NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Amgen Inc. (NASDAQ: AMGN)

 
AMGN Technical Analysis
1.5
As on 31st Oct 2017 AMGN Share Price closed @ 175.22 and we RECOMMEND Buy for LONG-TERM with Stoploss of 167.77 & Sell for SHORT-TERM with Stoploss of 180.70 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

AMGN Share Price

Open 174.15 Change Price %
High 176.19 1 Day 0.63 0.36
Low 174.15 1 Week 0.00 0.00
Close 175.22 1 Month -7.79 -4.26
Volume 2770325 1 Year 26.18 17.57
52 Week High 191.10 | 52 Week Low 138.83
 
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
INTC 45.49 2.52%
 
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
 
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
 
 
AMGN
Daily Charts
AMGN
Intraday Charts
Whats New @
Bazaartrend
AMGN
Free Analysis
 
AMGN Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE177.11
RESISTANCE176.33
SUPPORT174.11
SUPPORT173.33
SUPPORT0.00
SUPPORT0.00
 
AMGN Target for Month September
4th UP TARGET214.38
3rd UP TARGET201.82
2nd UP TARGET194.06
1st UP TARGET186.29
1st DOWN TARGET164.15
2nd DOWN TARGET156.38
3rd DOWN TARGET148.62
4th DOWN TARGET136.06
 
AMGN Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
AMGN Target for Year 2020
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
AMGN Other Details
Segment EQ
Market Capital 67280416768.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
AMGN Address
AMGN
One Amgen Center Drive
Thousand Oaks, CA 91320
United States
Phone: 805-447-1000
Fax: 805-447-1010
 
AMGN Latest News
 
Your Comments and Response on Amgen Inc.
 
AMGN Business Profile
Amgen Inc., incorporated on October 31, 1986, is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the outstanding stock of deCODE Genetics (deCODE). In July 5, 2012, the Company acquired KAI Pharmaceuticals, a privately held company based in South San Francisco. In June 12, 2012, the Company acquired substantially all of the outstanding stock of Mustafa Nevzat Pharmaceuticals (MN). In March 7, 2012, the Company acquired Micromet, Inc. (Micromet), a publicly held biotechnology company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. In September 2013, Swedish Orphan Biovitrum AB (publ) (Sobi) announced that they have acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen Inc for all therapeutic indications. The Company’s principal products include Neulasta, NEUPOGEN, ENBREL, Aranesp, EPOGEN, XGEVA and Prolia. Its principal products are Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection); Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in inflammatory diseases; Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa), erythropoiesis-stimulating agents (ESAs) that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab), two products that contain the same active ingredient but which are approved for different indications, patient populations, doses and frequencies of administration. In addition to its marketed products, the Company has various product candidates in mid-to late-stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience.
 
© 2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service